drugset / Trial / NCT01206335

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

NCT01206335 ↗

Phase 2 Unknown 20 enrolled Ohr Pharmaceutical Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.

Timeline

Start
2010-09
Primary completion
2012-12
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject OHR/AVR118 Unknown 4 ml Subcutaneous

Indications